Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial.
Share this article
Corporate
Score 85
Bullish
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
Mar 24, 2026 14:52 UTC
PFE, XLV, IHF
Short term
Related Articles
Score 35
7 Software Stocks Positioned to Benefit from AI Evolution, Analyst Says
Mar 24, 16:35
Score 65
Bullish
The Trade Desk to Partner With OpenAI? Here's What That Could Mean for the Stock
Mar 24, 16:20
Score 65
Bearish
Figma's Stock Is Trading Like Artificial Intelligence (AI) Will Destroy Its Business. But Is That Really the Case?
Mar 24, 16:20
Score 75
Bearish
Micron Stock Falls As Rival SK Hynix Ups Investments
Mar 24, 16:15
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.